Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2015

View Archived Issues

Epic's CTC technology reveals actionable liquid biopsy biomarkers for prostate and bladder cancer

CPE gene null mutation linked to severe obesity and other disorders

New company Lattice Biotech advances biofilm disruption technology

New bioinformatics tool as a filtering strategy for bacterial vaccine discovery

Oxis Biotech licenses rights to antibody-drug conjugates for cancer

Samsung Bioepis submits MAA to EMA for Remicade biosimilar

FDA approves Saphris for pediatric patients with bipolar I disorder

Baxter BioScience reports phase III data for BAX-817 in hemophilia A and B

Fujian Haixi announces FFAR1 agonists

First patient treated in Japanese phase III study of NK-kappaB decoy oligonucleotide

Bayer Schering Pharma patents novel SERMs

Merck & Co. patents himbacine derivatives as PAR-1 antagonists

Pfizer executes collaborative research agreement with National Cancer Center

Novel Dynamic BH3 profiling shows potential for guiding patient care

Edaravone given U.S. orphan status for amyotrophic lateral sclerosis

The Vanderbilt University reports Mcl-1 inhibitors

St. Jude Children's Research Hospital patents endopeptidase Clp activators

Indian CSIR patents antitumor pyrazolochalcones

Immune Design studies combinatorial regimen CMB-305 for NY-ESO-1-expressing cancers

Bendavia fails to reduce infarct size in first-time STEMI patients

WuXi PharmaTech to build new cell therapy manufacturing facility

FDA grants Exjade orphan designation for chronic iron overload in alpha-thalassemia

Reolysin receives two new U.S. orphan drug designations

Population Genetics Technologies and Case Western Reserve University to test HIV drug resistance

FDA orphan drug status conferred on propranolol hydrochloride/etodolac for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...